The CD40/CD40 ligand (CD40L) costimulatory system, which amplifies immune responses and can induce inflammation, is believed to have a role in skin manifestations of other autoimmune diseases ...

糖尿病，尤其是1型糖尿病（T1D），一直是一个困扰全球数百万患者的慢性疾病。许多患者每天需要注射胰岛素来控制血糖水平，这不仅给生活带来了不便，还伴随着一系列潜在的健康风险。那么，有没有可能让这些患者彻底摆脱胰岛素呢？最近的一项研究或许为我们带来了答案。 想象一下，如果有一种方法能够让糖尿病患者不再依赖胰岛素，那将是一个多么令人振奋的消息！近日，Eledon Pharmaceuticals公司公布了 ...

CD40–CD40L signaling may regulate both the initiation and effector phases of B- and T-cell responses, as well as transmigration of activated cells to target tissues. Direct therapy against this ...

One such molecule is the CD40L, which engages CD40 on dendritic and B cells of the immune system, enabling T cells to become activated as a result. Rodent studies using coreceptor blockade with ...

研究表明，阻断CD40L能够抑制多种共同刺激受体，包括CD40和CD11的激活，它们是免疫细胞之间相互交流的关键组成部分。阻断CD40L还能增加淋巴细胞向 ...

研究发现，cd40l从tfh转移至b淋巴细胞需要持续的cd40信号，并使抗原提呈b淋巴细胞在gc中存活和增殖。 CD40L从T淋巴细胞转移至B淋巴细胞的机制可能 ...

Frexalimab is described by Sanofi as a ‘second-generation’ anti-CD40L antibody that can block the costimulatory CD40/CD40L cellular pathway necessary for adaptive and immune cell activation ...

Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on Eledon Pharmaceuticals (ELDN – Research Report), retaining the price ...

Completed enrollment of Phase 2 BESTOW trial of tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline ...

The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad ...

加利福尼亚州尔湾 - Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)已为一项重大的承销发行定价,包括超过1800万股普通股和用于购买额外股份的预付权证,旨在筹集约8500万美元。普通股的定价为每股3.65美元,而预付权证的报价为每份3.649美元,可以0.001美元的价格行权购买每股。 这项财务举措计划于2024年10月30日完成交割,前提是满足标准的交割条件 ...